Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2016

01-06-2016 | Case Report

A Case Presenting with Splenic Infarct Diagnosed as Primary Bone Marrow CD5 Positive DLBCL: A Clinicopathological Correlation

Authors: Anupriya Bansal, Suchi Mittal, Jasmita Dass, Nitin Gupta, P. K. Agarwal, Jyoti Kotwal

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2016

Login to get access

Abstract

De novo CD5+ Diffuse large B cell lymphoma (DLBCL) is a rare and aggressive subtype of DLBCL. It is a distinct clinicopathologic entity with complex molecular profile and poor prognosis. A 59 year old female presented with pyrexia of unknown origin since 1 month. On examination, there was severe pallor, hepatosplenomegaly and no palpable lymphadenopathy. Complete blood count revealed bicytopenia with normal total leucocyte count. Liver and renal function tests were normal. Ultrasonography abdomen revealed splenic enlargement with two focal lesions attributed to either splenic abscess or infarcts. Patient was being managed as splenic infarct but continued to have bicytopenia. Further investigation showed elevated serum ferritin, triglycerides and LDH. With a clinical suspicion of infection and haemophagocytic lymphohistiocytosis bone marrow aspiration (BMA) and biopsy (BMBx) was done. BMA showed extensive haemophagocytosis and ~7.4 % large lymphoma-like cells. On this basis PET-CT was suggested which showed enlarged spleen with diffuse uptake. BMBx showed nodular and intrasinusoidal collection of abnormal lymphoid cells. On immunohistochemistry, these cells were positive for CD20, CD5, MUM1, BCL-2, BCL-6 and negative for CD3, CD10 and CD23. CD34 highlighted focal intrasinusoidal pattern. The complete clinicopathological profile suggested the diagnosis of de novo CD5+ DLBCL, with primary hepatosplenic pattern of involvement. CD5+ DLBCL presenting as splenic infarct is very rare. This case was unusual as the diagnosis of a primary aggressive lymphoma with haemophagocytosis was established in a patient who presented with fever and splenic infarct without lymphadenopathy. This indicates the importance of good morphological assessment of a bone marrow aspirate and biopsy to make a correct diagnosis.
Literature
1.
go back to reference Yamaguchi Motoko, Seto Masao, Okamoto Masataka, Ichinohasama Ryo, Nakamura Naoya, Yoshino Tadashi et al (2002) De novo CD5 diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815–821CrossRefPubMed Yamaguchi Motoko, Seto Masao, Okamoto Masataka, Ichinohasama Ryo, Nakamura Naoya, Yoshino Tadashi et al (2002) De novo CD5 diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815–821CrossRefPubMed
2.
go back to reference Ferry JA, Yang WI, Zukerberg LR, Wotherspoon AC, Arnold A, Harris NL (1996) CD5+ extranodal marginal zone B-cell (MALT) lymphoma: a low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 105:31–37CrossRefPubMed Ferry JA, Yang WI, Zukerberg LR, Wotherspoon AC, Arnold A, Harris NL (1996) CD5+ extranodal marginal zone B-cell (MALT) lymphoma: a low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 105:31–37CrossRefPubMed
3.
go back to reference Campo E, Swerdlow SH, Harris NL (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032CrossRefPubMedPubMedCentral Campo E, Swerdlow SH, Harris NL (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032CrossRefPubMedPubMedCentral
4.
go back to reference Harada S, Suzuki R, Uehira K (1999) Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+ and CD5− with CD10+ groups may constitute clinically relevant subtypes. Leukemia 13:1441–1447CrossRefPubMed Harada S, Suzuki R, Uehira K (1999) Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+ and CD5− with CD10+ groups may constitute clinically relevant subtypes. Leukemia 13:1441–1447CrossRefPubMed
5.
go back to reference Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S et al (2010) Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5- positive in comparison with CD-5 negative diffuse large B-cell lymphoma. Ann Oncol 21:2069–2074CrossRefPubMed Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S et al (2010) Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5- positive in comparison with CD-5 negative diffuse large B-cell lymphoma. Ann Oncol 21:2069–2074CrossRefPubMed
6.
go back to reference Dong HY, Gorczyca W, Liu Z, Tsang P, Wu CD, Cohen P et al (2003) B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol 119:218–230CrossRefPubMed Dong HY, Gorczyca W, Liu Z, Tsang P, Wu CD, Cohen P et al (2003) B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol 119:218–230CrossRefPubMed
7.
go back to reference Szyper-Kravitz M (2009) The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm. Isr Med Assoc J 11:633–634PubMed Szyper-Kravitz M (2009) The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm. Isr Med Assoc J 11:633–634PubMed
9.
go back to reference Shimazaki C, Inaba T, Okano A et al (2001) Clinical characteristics of B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS): comparison of CD5+ with CD5- B-LAHS. Intern Med 40:878–882CrossRefPubMed Shimazaki C, Inaba T, Okano A et al (2001) Clinical characteristics of B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS): comparison of CD5+ with CD5- B-LAHS. Intern Med 40:878–882CrossRefPubMed
10.
go back to reference Murase Takuhei, Yamaguchi Motoko, Suzuki Ritsuro, Okamoto Masataka, Sato Yumiko, Tamaru Jun-ichi et al (2007) Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 109:478–485CrossRefPubMed Murase Takuhei, Yamaguchi Motoko, Suzuki Ritsuro, Okamoto Masataka, Sato Yumiko, Tamaru Jun-ichi et al (2007) Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 109:478–485CrossRefPubMed
Metadata
Title
A Case Presenting with Splenic Infarct Diagnosed as Primary Bone Marrow CD5 Positive DLBCL: A Clinicopathological Correlation
Authors
Anupriya Bansal
Suchi Mittal
Jasmita Dass
Nitin Gupta
P. K. Agarwal
Jyoti Kotwal
Publication date
01-06-2016
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2016
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0646-2

Other articles of this Special Issue 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine